常见癌症生物标记物在分子诊断中的应用
Application of Biomarkers for Common Cancers in Molecular Diagnosis
DOI: 10.12677/MD.2019.91004, PDF,   
作者: 韩建冬, 王美玲, 格根塔娜, 杜艳青, 梁凤英, 额尔敦*：内蒙古医科大学，内蒙古 呼和浩特
关键词: 肿瘤；标记物；诊断；Cancer； Marker； Diagnosis
摘要: 越来越多的证据表明，基于靶标的药物仅在分子选择的患者群体中有活性。因此，预测性生物标志物的鉴定已成为改善这些新型药物的临床开发的必要条件。非小细胞肺癌中表皮生长因子受体(EGFR)的突变或ALK基因的重排以及黑素瘤中的BRAF突变是驱动突变的明显例子。预测性生物标志物还可以鉴定不太可能对特定药物有反应的患者亚组，如结肠直肠癌中的KRAS突变和抗EGFR单克隆抗体所示。新型驱动分子改变的发现和能够选择性阻断这种致癌机制的药物的可用性导致需要在每个单独患者中评估的推定生物标志物的数量的快速增加。在临床实践中引入这些技术将增加识别每个患者中的分子靶标的可能性，并且还允许在治疗期间跟踪疾病的分子进化。通过使用这些方法，最终可以为癌症患者开发个性化药物。
Abstract: There is increasing evidence that target-based drugs are only active in a population of selected molecules. Therefore, the identification of predictive biomarkers has become a necessary condition for improving the clinical development of these novel drugs. Mutation of the epidermal growth factor receptor (EGFR) or rearrangement of the ALK gene and BRAF mutation in melanoma in non-small cell lung cancer are clear examples of driving mutations. Predictive biomarkers can also identify subgroups of patients who are less likely to respond to a particular drug, such as KRAS mutations in colorectal cancer and anti-EGFR monoclonal antibodies. The discovery of novel driving molecule changes and the availability of drugs capable of selectively blocking this oncogenic mechanism have led to a rapid increase in the number of putative biomarkers that need to be evaluated in each individual patient. Introducing these techniques in clinical practice will increase the likelihood of identifying molecular targets in each patient and also allow for tracking the molecular evolution of the disease during treatment. By using these methods, personalized medicines can eventually be developed for cancer patients.
文章引用：韩建冬, 王美玲, 格根塔娜, 杜艳青, 梁凤英, 额尔敦. 常见癌症生物标记物在分子诊断中的应用[J]. 医学诊断, 2019, 9(1): 17-23. https://doi.org/10.12677/MD.2019.91004

参考文献

[1] Bergethon, K., Shaw, A.T., Ou, S.H., Katayama, R., Lovly, C.M., McDonald, N.T., Massion, P.P., Siwak-Tapp, C., Gonzalez, A., Fang, R., Mark, E.J., Batten, J.M., Chen, H., Wilner, K.D., Kwak, E.L., Clark, J.W., Carbone, D.P., Ji, H., Engelman, J.A., Mino-Kenudson, M., Pao, W. and Iafrate, A.J. (2012) ROS1 Rearrangements Define Aunique Molecular Class of Lung Cancers. Journal of Clinical Oncology, 30, 863-870. [Google Scholar] [CrossRef] 
[2] Carotenuto, P., Roma, C., Rachiglio, A.M., Botti, G., D’Alessio, A. and Normanno, N. (2010) Triple Negative Breast Cancer: From Molecular Portrait to Therapeutic Intervention. Critical Reviews in Eukaryotic Gene Expression, 20, 17-34.
[3] Carotenuto, P., Roma, C., Rachiglio, A.M., Tatangelo, F., Pinto, C., Ciardiello, F., Nappi, O., Iaffaioli, R.V., Botti, G. and Normanno, N. (2010) Detection of KRAS Mutations in Colorectal Carcinoma Patients with an Integrated PCR/Sequencing and Real-Time PCR Approach. Pharmacogenomics, 11, 1169-1179.
[4] Carvajal, R.D., Antonescu, C.R., Wolchok, J.D., Chapman, P.B., Roman, R.A., Teitcher, J., Panageas, K.S., Busam, K.J., Chmielowski, B., Lutzky, J., Pavlick, A.C., Fusco, A., Cane, L., Takebe, N., Vemula, S., Bouvier, N., Bastian, B.C. and Schwartz, G.K. (2011) KIT as a Therapeutic Target in Metastatic Melanoma. JAMA, 305, 2327-2334. [Google Scholar] [CrossRef] [PubMed]
[5] Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., Hogg, D., Lorigan, P., Lebbe, C., Jouary, T., Schadendorf, D., Ribas, A., O’Day, S.J., Sosman, J.A., Kirkwood, J.M., Eggermont, A.M.M., Dreno, B., Nolop, K., Li, J., Nelson, B., Hou, J., Lee, R.J., Flaherty, K.T. and McArthur, G.A. (2011) Improved Survival with Vemurafenib in Melanoma with BRAFV600E Mutation. The New England Journal of Medicine, 364, 2507-2516. [Google Scholar] [CrossRef] 
[6] De Luca, A. and Normanno, N. (2010) Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer. Current Drug Targets, 11, 851-864. [Google Scholar] [CrossRef] [PubMed]
[7] De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K.T., Kotoula, V., Papamichael, D., Laurent-Puig, P., Penault-Llorca, F., Rougier, P., Vincenzi, B., Santini, D., Tonini, G., Cappuzzo, F., Frattini, M., Molinari, F., Saletti, P., De Dosso, S., Martini, M., Bardelli, A., Siena, S., Sartore-Bianchi, A., Tabernero, J., Macarulla, T., Di Fiore, F., Gangloff, A.O., Ciardiello, F., Pfeiffer, P., Qvortrup, C., Hansen, T.P., Van Cutsem, E., Piessevaux, H., Lambrechts, D., Delorenzi, M. and Tejpar, S. (2010) Effects of KRAS, BRAF, NRAS, and PIK3C Amutations on the Efficacy of Cetuximab plus Chemotherapy in Chemotherapy-Refractory Metastatic Colorectal Cancer: A Retrospective Consortium Analysis. The Lancet Oncology, 11, 753-762.
[8] De Roock, W., De Vriendt, V., Normanno, N., Ciardiello, F. and Tejpar, S. (2010) KRAS, BRAF, PIK3CA, and PTEN Mutations: Implications for Targeted Therapies Inmetastatic Colorectal Cancer. The Lancet Oncology, 12, 594-603.
[9] De Roock, W., Jonker, D.J., Di Nicolantonio, F., Sar-tore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., Van Cutsem, E., O’Callaghan, C.J., Khambata-Ford, S., Zalcberg, J.R., Simes, J., Karapetis, C.S., Bardelli, A. and Tejpar, S. (2010) Association of KRAS p.G13D Mutation with Outcome in Patients with Chemotherapy-Refractory Metastatic Colorectal Cancer Treated with Cetuximab. JAMA, 304, 1812-1820.
[10] Diaz, L.A., Williams, R.T., Wu, J., Kinde, I., Hecht, J.R., Berlin, J., Allen, B., Bozic, I., Reiter, J.G., Nowak, M.A., Kinzler, K.W., Oliner, K.S. and Vogelstein, B. (2012) The Molecular Evolution of Acquired Resistance to Targeted EGFR Blockade in Colorectal Cancers. Nature, 486, 537-540. [Google Scholar] [CrossRef] [PubMed]
[11] Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Rich-ardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., Martin, N.M., Jackson, S.P., Smith, G.C. and Ash-worth, A. (2005) Targeting the DNA Repair Defect in BRCA Mutant Cells as a Therapeutic Strategy. Nature, 434, 917-921. [Google Scholar] [CrossRef] [PubMed]
[12] Flaherty, K.T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L.V., Hassel, J.C., Rutkowski, P., Mohr, P., Dummer, R., Trefzer, U., Larkin, J.M., Utikal, J., Dreno, B., Nyakas, M., Middleton, M.R., Becker, J.C., Casey, M., Sherman, L.J., Wu, F.S., Ouellet, D., Martin, A.M., Patel, K. and Schadendorf, D. (2012) Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. The New England Journal of Medicine, 367, 107-114. [Google Scholar] [CrossRef] 
[13] Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O’Connor, M.J., Ash-worth, A., Carmichael, J., Kaye, S.B., Schellens, J.H. and de Bono, J.S. (2009) Inhibition of Poly(ADP-ribose) Poly-merase in Tumors from BRCA Mutation Carriers. The New England Journal of Medicine, 361, 123-134. [Google Scholar] [CrossRef] 
[14] Fukuoka, M., Wu, Y.L., Thongprasert, S., Sunpaweravong, P., Leong, S.S., Sriuranpong, V., Chao, T.Y., Nakagawa, K., Chu, D.T., Saijo, N., Duffield, E.L., Rukazenkov, Y., Speake, G., Jiang, H., Armour, A.A., To, K.F., Yang, J.C. and Mok, T.S. (2011) Biomarker Analyses and Final Overall Survival Results from a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib versus Carboplatin/Paclitaxel in Clinically Selected Patients with Advanced Non-Small-Cell Lung Cancer in Asia (IPASS). Journal of Clinical Oncology, 29, 2866-2874. [Google Scholar] [CrossRef] 
[15] Gerber, D.E. and Minna, J.D. (2010) ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time. Cancer Cell, 18, 548-551. [Google Scholar] [CrossRef] [PubMed]
[16] Hauschild, A., Grob, J.-J., Demidov, L.V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C.U., Miller, W.H., Kaempgen, E., MartAn-Algarra, S., Karaszewska, B., Mauch, C., Chiarion-Sileni, V., Martin, A.-M., Swann, S., Haney, P., Mirakhur, B., Guckert, M.E., Goodman, V. and Chapman, P.B. (2012) Dabrafenib in BRAF-Mutated Metastatic Melanoma: A Multicentre, Open-Label, Phase 3 Randomised Controlled Trial. The Lancet, 380, 358-365. [Google Scholar] [CrossRef] 
[17] Hennessy, B.T., Gonzalez-Angulo, A.M., Stemke-Hale, K., Gilcrease, M.Z., Krishnamurthy, S., Lee, J.S., Fridlyand, J., Sahin, A., Agarwal, R., Joy, C., Liu, W., Stivers, D., Baggerly, K., Carey, M., Lluch, A., Monteagudo, C., He, X., Weigman, V., Fan, C., Palazzo, J., Hortobagyi, G.N., Nolden, L.K., Wang, N.J., Valero, V., Gray, J.W., Perou, C.M. and Mills, G.B. (2009) Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. Cancer Research, 69, 4116-4124. [Google Scholar] [CrossRef] 
[18] Herbst, R.S., Heymach, J.V. and Lippman, S.M. (2008) Lung Cancer. The New England Journal of Medicine, 359, 1367-1380. [Google Scholar] [CrossRef] 
[19] Jacobs, B., De Roock, W., Piessevaux, H., Van Oirbeek, R., Biesmans, B., De Schutter, J., Fieuws, S., Vandesompele, J., Peeters, M., Van Laethem, J.L., Humblet, Y., Penault-Llorca, F., De Hertogh, G., Laurent-Puig, P., Van Cutsem, E. and Tejpar, S. (2009) Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated with Cetuximab. Journal of Clinical Oncology, 27, 5068-5074.
[20] Khambata-Ford, S., Garrett, C.R., Meropol, N.J., Basik, M., Harbison, C.T., Wu, S., Wong, T.W., Huang, X., Takimoto, C.H., Godwin, A.K., Tan, B.R., Krishnamurthi, S.S., Burris, H.A. III, Poplin, E.A., Hidalgo, M., Baselga, J., Clark, E.A. and Mauro, D.J. (2007) Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated with Cetuximab. Journal of Clinical Oncology, 25, 3230-3237. [Google Scholar] [CrossRef] 
[21] MacConaill, L.E. and Garraway, L.A. (2010) Clinical Implications of the Cancer Genome. Journal of Clinical Oncology, 28, 5219-5228. [Google Scholar] [CrossRef] 
[22] Maheswaran, S., Sequist, L.V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C.V., Inserra, E., Diederichs, S., Iafrate, A.J., Bell, D.W., Digumarthy, S., Muzikansky, A., Irimia, D., Set-tleman, J., Tompkins, R.G., Lynch, T.J., Toner, M. and Haber, D.A. (2008) Detection of Mutations in EGFR in Circu-lating Lung-Cancer Cells. The New England Journal of Medicine, 359, 366-377. [Google Scholar] [CrossRef] 
[23] Marchetti, A., Felicioni, L., Malatesta, S., Grazia Sciarrotta, M., Guetti, L., Chella, A., Viola, P., Pullara, C., Mucilli, F. and Buttitta, F. (2011) Clinical Features and Outcome of Patients with Non-Small-Cell Lung Cancer Harboring BRAF Mutations. Journal of Clinical Oncology, 29, 3574-3579. [Google Scholar] [CrossRef] 
[24] Metzker, M.L. (2009) Sequencing Technologies—The Next Generation. Nature Reviews Genetics, 11, 31-46. [Google Scholar] [CrossRef] [PubMed]
[25] Miller, A.J. and Mihm, M.C. (2006) Melanoma. The New England Journal of Medicine, 355, 51-65. [Google Scholar] [CrossRef] 
[26] Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., Bencardino, K., Cercek, A., Chen, C.T., Veronese, S., Zanon, C., Sartore-Bianchi, A., Gambacorta, M., Gallicchio, M., Vakiani, E., Boscaro, V., Medico, E., Weiser, M., Siena, S., Di Nicolantonio, F., Solit, D. and Bardelli, A. (2012) Emergence of KRAS Mutations and Acquired Resistance to Anti-EGFR Therapy in Colorectal Cancer. Nature, 486, 532-536. [Google Scholar] [CrossRef] [PubMed]
[27] Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.J., Chewaskulyong, B., Jiang, H., Duffield, E.L., Watkins, C.L., Armour, A.A. and Fukuoka, M. (2009) Gefitinib or Carboplatin-Paclitaxel in Pulmonar Adenocarcinoma. The New England Journal of Medicine, 361, 947-957. [Google Scholar] [CrossRef] 
[28] Normanno, N., Bianco, C., De Luca, A., Maiello, M.R. and Salomon, D.S. (2003) Target-Based Agents against ErbB Receptors and Their Ligands: A Novel Approach to Cancer Treatment. Endocrine-Related Cancer, 10, 1-21.
[29] Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M.R., Carotenuto, A., De Feo, G., Caponigro, F. and Salomon, D.S. (2006) Epidermal Growth Factor Receptor (EGFR) Signaling in Cancer. Gene, 366, 2-16. [Google Scholar] [CrossRef] [PubMed]
[30] Normanno, N., Morabito, A., De Luca, A., Piccirillo, M.C., Gallo, M., Maiello, M.R. and Perrone, F. (2009) Target-Based Therapies in Breast Cancer: Current Status and Future Perspectives. Endocrine-Related Cancer, 16, 675-702.
[31] Normanno, N., Tejpar, S., Morgillo, F., De Luca, A., Van Cutsem, E. and Ciardiello, F. (2009) Implications for KRAS Status and EGFR-Targeted Therapies in Metastatic CRC. Endocrine-Related Cancer, 6, 519-527.
[32] Normanno, N., Pinto, C., Castiglione, F., Bardelli, A., Gambacorta, M., Botti, G., Nappi, O., Siena, S., Ciardiello, F., Taddei, G. and Marchetti, A. (2011) KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment. PLoS ONE, 6, e29146.
[33] O’Donovan, P.J. and Livingston, D.M. (2010) BRCA1 and BRCA2: Breast/Ovarian Cancer Susceptibility Gene Products and Participants in DNA Double-Strand Break Repair. Carcinogenesis, 31, 961-967. [Google Scholar] [CrossRef] [PubMed]
[34] Pao, W. and Hutchinson, K.E. (2012) Chipping away at the Lung Cancer Genome. Nature Medicine, 18, 349-351. [Google Scholar] [CrossRef] [PubMed]